{"success":true,"data":{"pressRelease":{"id":"46074","rtpr_id":"nBw19hR6Ya","ticker":"VRDN","exchange":"NASDAQ","all_tickers":["VRDN"],"title":"Viridian Therapeutics to Participate in Upcoming June Investor Conferences","author":"Business Wire","published_at":"2026-05-27T11:00:00.749Z","article_body":"Viridian Therapeutics to Participate in Upcoming June Investor Conferences\n\nViridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on\ndiscovering, developing, and commercializing potentially best-in-class\nmedicines for autoimmune and rare diseases, today announced that members of\nits management team will participate in the following upcoming investor\nconferences:\n\n\n * Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3,\n2026, at 5:30pm ET in New York, NY\n\n * Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on\nTuesday, June 9, 2026, at 4:00pm ET in Miami, FL\n\nA live webcast of each presentation can be accessed under “Events and\nPresentations” on the Investors section of the Viridian website at\nviridiantherapeutics.com. A replay will be available following each event.\n\nAbout Viridian Therapeutics\n\nViridian is a biotechnology company focused on discovering, developing, and\ncommercializing potential best-in-class medicines for patients with autoimmune\nand rare diseases. Viridian’s expertise in antibody discovery and protein\nengineering enables the development of differentiated therapeutic candidates\nfor validated drug targets and disease-driving mechanisms in autoimmune and\nrare diseases.\n\nViridian is advancing multiple late-stage, anti-insulin-like growth factor-1\nreceptor (IGF-1R) candidates in the clinic for the treatment of patients with\nthyroid eye disease (TED). The company conducted a pivotal program for\nveligrotug, including two global phase 3 clinical trials, THRIVE and THRIVE-2,\nto evaluate its efficacy and safety in patients with active and chronic TED.\nTHRIVE and THRIVE-2 reported positive topline data, meeting their primary\nendpoints and all secondary endpoints. Viridian is also advancing elegrobart\nas the potential first subcutaneous autoinjector for the treatment of TED.\nViridian is conducting an ongoing pivotal program for elegrobart, including\ntwo global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate\nthe efficacy and safety of elegrobart in patients with active and chronic TED.\nREVEAL-1 and REVEAL-2 reported positive topline data, meeting their primary\nendpoints and multiple secondary endpoints.\n\nIn addition to its IGF‑1R inhibitor portfolio, Viridian is developing an\nanti–thyroid‑stimulating hormone receptor (TSHR) program designed as a\npotential therapy for TED and Graves’ disease.\n\nViridian is also advancing a novel portfolio of neonatal Fc receptor (FcRn)\ninhibitors, including VRDN-006 and VRDN-008, which have the potential to be\ndeveloped in multiple autoimmune diseases.\n\nViridian is based in Waltham, Massachusetts. For more information, please\nvisit www.viridiantherapeutics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.viridiantherapeutics.com&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=www.viridiantherapeutics.com&index=1&md5=d315a3fc6ca3c507d604e9e897495ae3)\n. Follow Viridian on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fviridiantx&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=LinkedIn&index=2&md5=1059c90fcf16f6b455cfb7e741cd3294)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FViridianThera&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=X&index=3&md5=c7b5c1c9067f16729cd23066c0e26371)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527884415/en/\n(https://www.businesswire.com/news/home/20260527884415/en/)\n\nInvestors \n\nGreg Rossino\n\ngrossino@viridiantherapeutics.com (mailto:grossino@viridiantherapeutics.com)\n\nMedia \n\nLisa Lopez\n\nllopez@viridiantherapeutics.com (mailto:llopez@viridiantherapeutics.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw19hR6Ya","title":"Viridian Therapeutics to Participate in Upcoming June Investor Conferences","author":"Business Wire","ticker":"VRDN","created":"2026-05-27T11:00:00.749Z","tickers":["VRDN"],"exchange":"NASDAQ","article_body":"Viridian Therapeutics to Participate in Upcoming June Investor Conferences\n\nViridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on\ndiscovering, developing, and commercializing potentially best-in-class\nmedicines for autoimmune and rare diseases, today announced that members of\nits management team will participate in the following upcoming investor\nconferences:\n\n\n * Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3,\n2026, at 5:30pm ET in New York, NY\n\n * Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on\nTuesday, June 9, 2026, at 4:00pm ET in Miami, FL\n\nA live webcast of each presentation can be accessed under “Events and\nPresentations” on the Investors section of the Viridian website at\nviridiantherapeutics.com. A replay will be available following each event.\n\nAbout Viridian Therapeutics\n\nViridian is a biotechnology company focused on discovering, developing, and\ncommercializing potential best-in-class medicines for patients with autoimmune\nand rare diseases. Viridian’s expertise in antibody discovery and protein\nengineering enables the development of differentiated therapeutic candidates\nfor validated drug targets and disease-driving mechanisms in autoimmune and\nrare diseases.\n\nViridian is advancing multiple late-stage, anti-insulin-like growth factor-1\nreceptor (IGF-1R) candidates in the clinic for the treatment of patients with\nthyroid eye disease (TED). The company conducted a pivotal program for\nveligrotug, including two global phase 3 clinical trials, THRIVE and THRIVE-2,\nto evaluate its efficacy and safety in patients with active and chronic TED.\nTHRIVE and THRIVE-2 reported positive topline data, meeting their primary\nendpoints and all secondary endpoints. Viridian is also advancing elegrobart\nas the potential first subcutaneous autoinjector for the treatment of TED.\nViridian is conducting an ongoing pivotal program for elegrobart, including\ntwo global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate\nthe efficacy and safety of elegrobart in patients with active and chronic TED.\nREVEAL-1 and REVEAL-2 reported positive topline data, meeting their primary\nendpoints and multiple secondary endpoints.\n\nIn addition to its IGF‑1R inhibitor portfolio, Viridian is developing an\nanti–thyroid‑stimulating hormone receptor (TSHR) program designed as a\npotential therapy for TED and Graves’ disease.\n\nViridian is also advancing a novel portfolio of neonatal Fc receptor (FcRn)\ninhibitors, including VRDN-006 and VRDN-008, which have the potential to be\ndeveloped in multiple autoimmune diseases.\n\nViridian is based in Waltham, Massachusetts. For more information, please\nvisit www.viridiantherapeutics.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.viridiantherapeutics.com&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=www.viridiantherapeutics.com&index=1&md5=d315a3fc6ca3c507d604e9e897495ae3)\n. Follow Viridian on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fviridiantx&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=LinkedIn&index=2&md5=1059c90fcf16f6b455cfb7e741cd3294)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FViridianThera&esheet=54542304&newsitemid=20260527884415&lan=en-US&anchor=X&index=3&md5=c7b5c1c9067f16729cd23066c0e26371)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260527884415/en/\n(https://www.businesswire.com/news/home/20260527884415/en/)\n\nInvestors \n\nGreg Rossino\n\ngrossino@viridiantherapeutics.com (mailto:grossino@viridiantherapeutics.com)\n\nMedia \n\nLisa Lopez\n\nllopez@viridiantherapeutics.com (mailto:llopez@viridiantherapeutics.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-27T11:00:00.845527858Z","server_sent_at_ms":1779879600845},"received_at":"2026-05-27T11:00:01.048Z","source_url":"https://www.businesswire.com/news/home/20260527884415/en/"},"analysis":{"id":"35507","press_release_id":"46074","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Viridian Therapeutics announced that management will participate in two upcoming investor conferences in June 2026.\n\nThe company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 3 in New York and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami.\n\nLive webcasts and replays of the presentations will be available on the company's investor relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference schedule -- low signal."},"keyFigures":{},"quotedText":"Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences","namedEntities":{"people":[{"name":"Greg Rossino","role":"Investor Relations"},{"name":"Lisa Lopez","role":"Media Relations"}],"products":["veligrotug","elegrobart","VRDN-006","VRDN-008"],"companies":[{"name":"Viridian Therapeutics, Inc.","ticker":"VRDN"},{"name":"Jefferies","relationship":"conference host"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of participation in upcoming investor conferences. No new clinical data, financial results, or strategic developments disclosed."},"tickerRelevance":{"others":[],"primary":"VRDN"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_conference","sectorWeight":"biotech","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Viridian Therapeutics announced that management will participate in two upcoming investor conferences in June 2026.\n\nThe company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 3 in New York and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami.\n\nLive webcasts and replays of the presentations will be available on the company's investor relations website.","key_figures":{},"named_entities":{"people":[{"name":"Greg Rossino","role":"Investor Relations"},{"name":"Lisa Lopez","role":"Media Relations"}],"products":["veligrotug","elegrobart","VRDN-006","VRDN-008"],"companies":[{"name":"Viridian Therapeutics, Inc.","ticker":"VRDN"},{"name":"Jefferies","relationship":"conference host"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-27T11:02:02.226Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_conference","sectorWeight":"biotech","issuerAuthored":true}},"durationMs":14260,"modelName":"george-droid-qwen-72b"}}